BE887518A - Cartothioates d'androstanes - Google Patents

Cartothioates d'androstanes

Info

Publication number
BE887518A
BE887518A BE0/203794A BE203794A BE887518A BE 887518 A BE887518 A BE 887518A BE 0/203794 A BE0/203794 A BE 0/203794A BE 203794 A BE203794 A BE 203794A BE 887518 A BE887518 A BE 887518A
Authority
BE
Belgium
Prior art keywords
cartothioates
androstan
androstan cartothioates
Prior art date
Application number
BE0/203794A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BE887518A publication Critical patent/BE887518A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE0/203794A 1980-02-15 1981-02-13 Cartothioates d'androstanes BE887518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8005174 1980-02-15

Publications (1)

Publication Number Publication Date
BE887518A true BE887518A (fr) 1981-08-13

Family

ID=10511390

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/203794A BE887518A (fr) 1980-02-15 1981-02-13 Cartothioates d'androstanes

Country Status (8)

Country Link
US (1) US4335121A (fr)
JP (1) JPS56138200A (fr)
BE (1) BE887518A (fr)
CA (1) CA1201114A (fr)
EC (1) ECSP941097A (fr)
PH (1) PH24267A (fr)
ZA (1) ZA81976B (fr)
ZW (1) ZW18081A1 (fr)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861765A (en) * 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
JPH0231703A (ja) * 1988-07-22 1990-02-01 Sukai:Kk 口紅付きリップブラシ
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
YU48707B (sh) * 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
EP0617610B1 (fr) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Formulations d'aerosol en suspension
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
MX9707864A (es) * 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
KR19980703850A (ko) 1995-04-14 1998-12-05 그레이엄브레레톤 베클로메타손 디프로피오네이트용 계량 흡입기
MX9707862A (es) * 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
AP791A (en) * 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
US5993782A (en) * 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
US20020133032A1 (en) * 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
WO2002012266A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002024552A2 (fr) 2000-09-18 2002-03-28 Glaxo Group Limited Recipient d'aerosol doseur recouvert deux fois ou plus de polymeres de fluorocarbure
WO2002080859A2 (fr) * 2001-03-20 2002-10-17 Glaxo Group Limited Associations de medicaments administrees par inhalation
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
PT1383786E (pt) * 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US20040248867A1 (en) * 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AU2002321884A1 (en) * 2001-08-03 2003-02-24 Smithkline Beecham Corporation A method for preparing fluticasone derivatives
GB0202563D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1534733A2 (fr) * 2002-06-20 2005-06-01 Sun Pharmaceuticals Industries Ltd. Synthese adaptee de s-fluoromethyl 6alpha,9alpha-difluoro-11beta-hydroxy-16alpha-methyl-17alpha-propionyloxy-3-oxoandrosta-1,4-diene-17beta-carbothioate
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004060260A2 (fr) * 2002-12-18 2004-07-22 Glaxo Group Limited Systeme d'administration de medicament dote d'un embout buccal a event
WO2004087731A1 (fr) * 2003-04-04 2004-10-14 Alpharma Aps Methode de preparation de derives et d'intermediaires d'acides carbothioiques steroides
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患(copd)のための組合せ治療法
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Iv型ホスホジエステラーゼの阻害剤
CA2538237A1 (fr) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
EP1526139A1 (fr) * 2003-10-24 2005-04-27 S.N.I.F.F. Italia S.P.A. Procédé pour la préparation d'acides 17-beta-carboxyliques d'androstane et d'esters fluorométhylés de l'acide 17-beta-carboxylique d'androstane de haute pureté
EP1694655A2 (fr) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
AU2004294889B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
WO2006011148A2 (fr) * 2004-07-26 2006-02-02 Chemagis Ltd. Nouvelles formes cristallines d'acide 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene-17beta-carboxylique et procede de preparation
PT103202B (pt) * 2004-10-19 2011-01-27 Hovione Farmaciencia S A Processo para a esterificação de um ácido carbotiótico
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
EP1940863B1 (fr) 2005-09-02 2012-09-05 Nicox S.A. Nitro-oxyderives de steroides de glucocorticoides
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
WO2007045980A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
US20100130460A1 (en) * 2005-12-09 2010-05-27 Nycomed Us Inc. Topical glucocorticosteroid formulations
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
AU2013202835B2 (en) * 2006-06-14 2015-11-12 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
EP2402360B1 (fr) * 2006-06-14 2020-04-01 Generics [UK] Limited Procédé pour la préparation de S-fluorométhyl-6,9-difluoro-11-hydroxy-16-méthyl-17-propionyloxy-3-oxo-androsta-1,4-diène-17-carbothioate et intermédiaires
GB0612027D0 (en) * 2006-06-16 2006-07-26 Glaxo Group Ltd Novel process
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
SI2046787T1 (sl) 2006-08-01 2011-07-29 Glaxo Group Ltd Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
WO2008111009A1 (fr) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
US20080318915A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched fluticasone propionate
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
US8796248B2 (en) 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
US7935837B2 (en) * 2008-04-30 2011-05-03 Corum Inc. Process for synthesis of androstane 17-β carbothioic acid and relative compounds thereof
WO2010025236A1 (fr) * 2008-08-27 2010-03-04 Alexander Goldin Composition et procédé pour traiter le rhume
AU2010219097A1 (en) 2009-01-13 2011-08-04 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
NZ624922A (en) 2009-10-01 2016-05-27 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
WO2011093813A1 (fr) 2010-01-28 2011-08-04 Mahmut Bilgic Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
WO2011093811A2 (fr) 2010-01-29 2011-08-04 Mahmut Bilgic Préparations pharmaceutiques comprenant du formotérol et du fluticasone
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
EP2563364A1 (fr) 2010-04-26 2013-03-06 Mahmut Bilgic Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2011141929A2 (fr) 2010-05-11 2011-11-17 Cadila Healthcare Limited Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine
JP2013536835A (ja) * 2010-09-01 2013-09-26 カディラ・ヘルスケア・リミテッド プロピオン酸/フロ酸フルチカゾンを調製するための方法
WO2012056201A2 (fr) 2010-10-27 2012-05-03 Hovione Inter Limited Réactifs électrophiles pour monohalométhylation, leur préparation et leurs utilisations
CN102558273B (zh) 2010-12-14 2014-07-02 浙江省天台县奥锐特药业有限公司 氟替卡松糠酸酯的制备方法
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2014007772A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation contenant du glucose anhydre
WO2014007770A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
WO2014007781A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation
WO2014007771A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
SG11201509680TA (en) 2013-05-28 2015-12-30 Sun Pharma Advanced Res Co Ltd Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
US20160129207A1 (en) 2013-06-17 2016-05-12 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
US9796750B2 (en) 2014-02-07 2017-10-24 Mylan Laboratories Ltd. Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent
US9303060B1 (en) 2014-10-03 2016-04-05 Amphaster Pharmaceuticals, Inc. Methods of preparing intermediate of fluticasone propionate
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN110698530A (zh) * 2019-10-30 2020-01-17 山东赛托生物科技股份有限公司 一种丙酸氟替卡松的合成方法
PT4197528T (pt) 2021-07-09 2024-06-06 Astrazeneca Pharmaceuticals Lp Composições, métodos e sistemas para administração de fármacos em aerossol
US20250057764A1 (en) 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives

Also Published As

Publication number Publication date
JPS6337120B2 (fr) 1988-07-22
CA1201114A (fr) 1986-02-25
ZA81976B (en) 1982-07-28
ZW18081A1 (en) 1981-10-21
PH24267A (en) 1990-05-29
US4335121A (en) 1982-06-15
JPS56138200A (en) 1981-10-28
ECSP941097A (es) 1995-01-16

Similar Documents

Publication Publication Date Title
BE887518A (fr) Cartothioates d'androstanes
BE875773A (nl) 2'deoxy-5-(halogeenvinyl)-uridines
TR21767A (tr) N-fenilsulfonil-n'-pirimidinil-ve-triazinilureler
BE879683A (fr) Strijkpapierbekledingsmassa's met hoge vaste-stofconcentratie
LT2397B (lt) Dantu iklotu sudetis
DK163246C (da) 4'-keto-n-trifluoracetyldaunorubicin
BE876123A (fr) Installation d'ascenseur
ATE202T1 (de) 2-cycloalkyl-pyrimidin(5)
BE876795A (fr) Installation d'ensachage
DE3141464A1 (de) "kopiergeraet"
FR2427285B1 (fr) Installation d'ascenseur
BE876388A (fr) Installation d'ascenseur
LU81071A1 (fr) Vitrai 12
BE896957A (fr) Vecteur d'expression
IT1157288B (it) Agenti anti-obesita'
BE893837A (fr) Vecteurs d'expression
SU1179923A3 (ru) "cпocoб пoлучehия aзoлилпehtehпpoизboдhыx"
FI790141A7 (fi) 2 6-dinitrobensenaminer
SU1178335A3 (ru) "иhдиkatophый элemeht для элektpoлюmиhecцehthoгo эkpaha"
BE883955A (fr) "limnimetre"
BE885171A (fr) Installation d'acenseur
NO822578L (no) Tilhengerfeste
BE883954A (fr) "spanningsverzorgingsschakeling"
RO84326A (fr) Compresseur d'agent frigorigene
IT7866310A0 (it) Tiche'

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 094C0001

CCPV Grant of a supplementary protection certificate

Free format text: 094C0001, EXPIRES 20050308

RE20 Patent expired

Owner name: GLAXO GROUP LTD

Effective date: 20010213

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME FLUTICASONE PROPIONATE (MICRONISE); NAT. REG. NO/DATE 276 S 660 F 11/19931202; FIRST REG GB/PL0045/0153 19900308

Spc suppl protection certif: 94C0001

Filing date: 19951031

Expiry date: 20010213

Extension date: 20050308

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: FLUTICASONE PROPIONATE (MICRONISE); NAT. REG.: 276 S 660 F 11 19931202;FIRST REG.: GBPL0045/0153 19900308

Spc suppl protection certif: 94C0001

Filing date: 19940119

Expiry date: 20010213

Extension date: 20050308